798 related articles for article (PubMed ID: 26308779)
1. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
2. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
5. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
[TBL] [Abstract][Full Text] [Related]
7. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients.
Saukkonen K; Garland R; Koziel H
Chest; 1996 May; 109(5):1250-5. PubMed ID: 8625676
[TBL] [Abstract][Full Text] [Related]
8. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
Carr A; Tindall B; Penny R; Cooper DA
AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.
Evans RA; Clifford TM; Tang S; Au T; Fugit AM
Transpl Infect Dis; 2015 Dec; 17(6):816-21. PubMed ID: 26369753
[TBL] [Abstract][Full Text] [Related]
10. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
[TBL] [Abstract][Full Text] [Related]
11. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.
Gabardi S; Millen P; Hurwitz S; Martin S; Roberts K; Chandraker A
Clin Transplant; 2012; 26(3):E184-90. PubMed ID: 22487221
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
[TBL] [Abstract][Full Text] [Related]
15. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
Fisher RG; Nageswaran S; Valentine ME; McKinney RE
AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
[TBL] [Abstract][Full Text] [Related]
16. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
[TBL] [Abstract][Full Text] [Related]
17. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.
Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Tomita M; Kihara M; Yokoyama W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Kohsaka H; Miyasaka N; Harigai M
Arthritis Res Ther; 2017 Jan; 19(1):7. PubMed ID: 28100282
[TBL] [Abstract][Full Text] [Related]
18. Higher risk of urinary tract infections in renal transplant recipients receiving pentamidine versus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia prophylaxis.
Fu W; Barahona M; Harkness T; Cohen E; Reardon D; Yoo PS
Clin Transplant; 2020 Nov; 34(11):e14067. PubMed ID: 32810885
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience.
Borstnar S; Lindic J; Tomazic J; Kandus A; Pikelj A; Prah J; Skvarc M; Godnov U; Kovac D
Transplant Proc; 2013 May; 45(4):1614-7. PubMed ID: 23726632
[TBL] [Abstract][Full Text] [Related]
20. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study.
Otani T; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
Pulm Pharmacol Ther; 2021 Apr; 67():101999. PubMed ID: 33571651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
